HOME >> MEDICINE >> NEWS
Lexapro receives FDA approval for the treatment of generalized anxiety disorder

NEW YORK, December 18 - Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Lexapro (escitalopram oxalate), a selective serotonin reuptake inhibitor (SSRI), for the treatment of generalized anxiety disorder (GAD), a condition that affects approximately four million Americans annually. The new indication is based on three studies, all of which were positive and support the efficacy and safety of Lexapro in the treatment of GAD. GAD is characterized by excessive anxiety and worry that significantly impacts an individual's daily functioning. Lexapro is also indicated for the initial treatment and maintenance of major depressive disorder.

"One of the biggest challenges in treating GAD patients is finding a treatment that is not only effective, but also one that patients will be able to tolerate for the long term," said Philip Ninan, M.D., professor of Psychiatry and Behavioral Sciences and director of the Mood and Anxiety Disorders Program at Emory University School of Medicine. "Lexapro is a first-line treatment option, which has proven to be effective with a favorable side effect profile."

Study Details

All three studies that support the indication approval were randomized, double-blind, eight weeks in duration and placebo-controlled. The studies involved approximately 850 patients, 18 to 80 years of age, diagnosed with GAD. Patients in the Lexapro arm were administered a fixed dose of 10 mg per day for the first four weeks and then flexibly dosed to a maximum of 20 mg per day. The Hamilton Anxiety Scale (HAMA) total score was the primary efficacy variable, and secondary efficacy measures included changes in HAMA psychic anxiety subscale and Clinical Global Impressions (CGI) scores. In each of the three studies, Lexapro 10 to 20 mg per day significantly improved GAD symptoms in patients compared to placebo as measured by change from baseline in HAMA score. By-visit anal
'"/>

Contact: Charles E. Triano
212-224-6714
Forest Laboratories
18-Dec-2003


Page: 1 2

Related medicine news :

1. Starting dose of Lexapro as effective as optimally dosed Zoloft in the treatment of depression
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 According to ... Vkool.com, this is a comprehensive fitness guide that teaches men ... per week. , Vkool reveals in its review that ... discover:, Ways to gain the maximum ... to build muscle and avoid fat gain , ...
(Date:7/28/2014)... July 28, 2014 TherapySites, ... health professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue to extend ... benefits and promotional offers. , “There has been a ... today. With nearly 3 billion Internet users, it ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 CW4K was ... First Lady Michelle Obama and Partnership for a ... as they join the group's DrinkUP effort, ... water, more often. , The seven organizations added ... Nalgene® Outdoor Products, S’well Bottle, Santa Clara Valley Water ...
(Date:7/28/2014)... July 28, 2014 Footwear etc. is ... styles from Mephisto. With shoes, sandals, and boots that ... products continually provide handmade comfort shoes and ... women have come to rely on the superb value, ... Mephisto shoes and sandals contain the highest quality materials ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... and LONDON , July 28, 2014 ... to create and commercialize companion diagnostic using genomic data ...  for non-small cell lung cancer patients  New ... test and is planned to run on Rotor-Gene Q, member of ... enabled by AstraZeneca master framework agreement adds to QIAGEN,s ...
(Date:7/28/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... second quarter 2014 financial results on Monday, August 4, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Monday, August 4 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
Cached News: